Propofol and etomidate. Are they also safe for patients with Brugada-Syndrome?

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON24665

Enrollment

Registered

2012-02-28

Start date

2012-03-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brugada-Syndrome, Propofol, Etomidate, Arrhythmia,

Interventions

Administration of propofol versus etomidate for induction of anaesthesia in patients screened for Brugada Syndrome. After obtaining eligibility with the patient profile (in- and exclusion criteria)

Eligibility

Inclusion criteria

Inclusion criteria: All paediatric and adult patients that have been screened for BrS and were found positive before or after the Ajmaline-test are included.

Exclusion criteria

Exclusion criteria: 1. Patients with a known allergy for soya are excluded from the study; 2. Patients with a supressed immune-status are excluded from the study; 3. Patients with a recent transient ischemic attack or cerebrovascular accident will be excluded from the study.

Design outcomes

Primary

Measure	Time frame
ECG changes. ST elevation of 1 or more mm which is described as type I, or coved.	—

Contacts

Public ContactVeerle Mossevelde, van

Laarbeeklaan 101

veerle.vanmossevelde@uzbrussel.be+32 (0)2 4763134

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)